www.scotusblog.com/case-files/cases/amgen-inc-v-sanofi

Dec 04 2018, Reply of petitioners Amgen Inc., et al. filed. (Distributed). Dec 05 2018, DISTRIBUTED for Conference of 1/4/2019. Jan 07 2019, Petition DENIED.

antitrustconnect.com/2016/05/16/eisai-v-sanofi-aventis-third-circuit-leaves-door-open-to-loyalty-discount-liability

May 16, 2016 ... Eisai v Sanofi-Aventis: Third Circuit Leaves Door Open to Loyalty ... have threatened to terminate supply if customers didn't meet all (or most) of ...

blog.petrieflom.law.harvard.edu/2017/07/02/more-on-the-ecj-vaccine-liability-decision

Jul 2, 2017 ... This is likely to be the case with the European Court of Justice (ECJ) decision on vaccine manufacturers' liability, N.W. et al. v. Sanofi Pasteur ...

www.gpo.gov/fdsys/granule/USCOURTS-paed-2_02-cv-02964/USCOURTS-paed-2_02-cv-02964-2/content-detail.html

Jan 10, 2017 ... ... STATES OF AMERICA ex rel. YOASH GOHIL v. AVENTIS PHARMACEUTICALS, INC. et al. ... SANOFI-AVENTIS U.S. INC., Defendant

law.justia.com/cases/federal/appellate-courts/ca10/12-3085/12-3085-2013-01-14.html

Rangel v. Sanofi Aventis, No. 12-3085 (10th Cir. 2013) case opinion from the U.S. Court of Appeals for the Tenth Circuit.

caselaw.findlaw.com/us-3rd-circuit/1733563.html

Case opinion for US 3rd Circuit EISAI INC v. SANOFI AVENTIS LLC. Read the Court's full decision on FindLaw.

products.sanofi.ca/en/flagyl.pdf

Aug 7, 2018 ... sanofi-aventis Canada Inc. ... s-a Version 10.0 dated August 7, 2018 .... has been observed in all six reported studies in that species, ..... Intravenous metronidazole vs oral erythromycin base plus neomycin in the prevention of ... Toxicité et propriétés pharmacologiques générales. ..... tingling sensation on.